Happy #SocialMediaDay!!! The Center for Devices and Radiological Health at the FDA remain committed to sharing important information with you via various social media platforms. Follow us on X at https://lnkd.in/euhrrJRE and stay informed on Facebook and LinkedIn as well.
About us
The Food and Drug Administration is an agency within the Department of Health and Human Services. The FDA is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation. FDA also has responsibility for regulating the manufacturing, marketing, and distribution of tobacco products to protect the public health and to reduce tobacco use by minors. FDA is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health. FDA also plays a significant role in the Nation's counterterrorism capability. FDA fulfills this responsibility by ensuring the security of the food supply and by fostering development of medical products to respond to deliberate and naturally emerging public health threats.
- Website
-
http://www.fda.gov/
External link for FDA
- Industry
- Government Administration
- Company size
- 10,001+ employees
- Headquarters
- Silver Spring, MD
- Type
- Government Agency
- Specialties
- Food, Drugs, Medical Devices, Vaccines Blood and Biologics, Animal and Veterinary, Cosmetics, Radiation-Emitting Products, Tobacco Products, Regulatory Research, and Toxicological Regulatory Research
Locations
-
Primary
Get directions
10903 New Hampshire Ave
Silver Spring, MD 20993, US
Employees at FDA
Updates
-
❓ Ever wonder about the role of nanomaterials in drug products and what factors to consider? 💡 Read, listen and learn at: https://lnkd.in/eVcWBTjQ
-
-
This week, FDA’s Center for Tobacco Products updated the presentation of information about tobacco compliance check outcomes on the FDA website and expanded the information available. The newly-named Tobacco Compliance Check Outcomes database provides an enhanced user experience by housing results of all tobacco retail inspection outcomes in a single location. Learn more: https://lnkd.in/dyy4xSB8
-
-
🌟 As healthcare providers, staying updated with the latest treatment options is crucial for delivering the best patient care. The FDA’s Purple Book is a valuable tool that encompasses detailed information on FDA-licensed biological products, including #biosimilars, interchangeable medications, and their reference biologics. Learn more about this free resource here: https://bit.ly/4dOTTIR
-
-
FDA issued a new guidance to help ensure that a device’s drug-delivery function consistently performs as intended including for prefilled syringes, injectors, nasal sprays, and inhalation devices: https://lnkd.in/eGd2hREH FDA welcomes comments on this draft guidance. We encourage interested parties to submit comments by September 29, 2024, to ensure consideration before FDA begins work to finalize this guidance: https://lnkd.in/eXK4wRSa
-
📑 Research shows that treatment of OUD is most effective when medications are used. If you or someone you know has been impacted by OUD, speak with a prescriber today: https://lnkd.in/d-W9FV-F
Most adults who needed opioid use disorder (OUD) treatment in 2022 did not receive medications for OUD. According to a new CDC report, higher percentages of non-Hispanic White adults received any OUD treatment compared with non-Hispanic Black and Hispanic or Latino adults. Recovery is possible. Learn more: https://bit.ly/45FOvnX
-
-
FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) initiated the START Pilot Program with hopes that the insight gained through this pilot will provide information on how best to facilitate more efficient development of potentially life-saving therapies for rare diseases and help sponsors generate high-quality, actionable data to support future new drug or biologics license applications. Through the START Pilot Program, the opportunity for increased engagement with the selected sponsors should facilitate more rapid achievement of regulatory milestones. Learn more in the latest "From Our Perspective" article ➡https://lnkd.in/gSBJmXbs
-
-
Today, we announced that we are granting marketing authorization to Cepheid for the Xpert HCV test performed on the GeneXpert Xpress System. This is the first point-of-care hepatitis C (HCV) ribonucleic acid (RNA) test and offers one-hour testing, so people can get faster linkage to care. This will potentially reduce deaths from hepatitis C, a cause of liver cancer and liver failure. The new tests can be used in doctors’ offices, community-based clinics, urgent care centers, outpatient health care facilities, and emergency rooms. Learn more: https://lnkd.in/drxWMNfj
-
-
Learn how CDER researchers have made use of lectins as probes to devise a method for analyzing a critical quality attribute of antibody-based therapeutics in the latest Regulatory Science Impact Story: https://lnkd.in/e27uHzEw
-
-
Did You Know? In 2021, approximately $11.7 million was spent each day on promoting the top 10 prescription drugs alone. Learn more about prescription drug promotion and FDA’s Bad Ad Program: http://www.fda.gov/BadAd #FDABadAd
-